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Sildenafil (Viagra
®; Pfizer US Pharmaceutical Group, New York, NY, USA) is a
selective, potent inhibitor of cGMP-specific phosphodiesterase 5, which increases
the cGMP concentration by inhibiting the hydrolysis of cGMP to GMP.
1 It has
been shown to have antinociceptive effects in the formalin test in rats and in the
writhing response induced by acetic acid and zymosan in mice,
2-8 which is medi-
ated through the nitric oxide (NO)-cGMP-potassium channel pathway.
4,6,8,9
Recently, intrathecal sildenafil was reported to produce antinociceptive effects,
mediated through GABAB and opioid receptors.
5,10
Experimental data indicate that adenosine and serotonin act by modulating noci-
ceptive transmission at the spinal level, mediated through the respective recep-
tors.
11-17 Recently, it was reported that sildenafil inhibited the anticonvulsant effect
of adenosine.
18 Additionally, dipyridamole, another type of phosphodiesterase 5
inhibitor, inhibited vasoconstriction induced by serotonin.
19 These observations
suggest that the effects of the cGMP-specific phosphodiesterase inhibitor are
affected by both the adenosine and serotonin systems. However, the roles of spinal
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Purpose: The phosphodiesterase 5 inhibitor sildenafil has antinociceptive effects,
mediated by an increase in cGMP. This study examined the role of spinal
adenosine and serotonin receptors played in the antinociceptive effects of intrathe-
cal sildenafil. Materials and Methods: Intrathecal catheters were inserted into the
subarachnoid space of Sprague-Dawley male rats as a drug delivery device. Pain
was induced by injecting formalin into the plantar surface of rats and observing
nociceptive behavior (flinching response) for 60 mininutes. Then, the effects of
intrathecal adenosine and serotonin receptor antagonists on the antinociceptive
activity of intrathecal sildenafil were examined. Results: Intrathecal sildenafil
suppressed the flinching response in a dose-dependent manner during phases 1 and
2 in the formalin test. Both CGS 15943 and dihydroergocristine decreased the
antinociceptive effects of sildenafil during phases 1 and 2 in the formalin test.
Conclusion: Intrathecal sildenafil effectively attenuated the pain evoked by
formalin injection. Both adenosine and serotonin receptors may be involved in the
antinociceptive action of sildenafil at the spinal level. 
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INTRODUCTIONadenosine and serotonin receptors in the antinociceptive
effect of intrathecal sildenafil remain to be determined.
Thus, this study investigated the effects of intrathecal
sildenafil in a formalin-induced nociception model of rat and
then determined the roles of adenosine and serotonin recep-
tors played in the effects of sildenafil at the spinal level.
Animal preparation
The Institutional Animal Care Committee, Research Insti-
tute of Medical Science of Chonnam National University,
approved these experimental procedures.
Sprague-Dawley adult male rats (8-weeks-old, weighing
250-300 g) were used in these experiments. The rats were
housed in a vivarium maintained at 20-23˚C with 12-hour
light/dark cycle and were given food and water ad libitum. 
For spinal drug administration, a polyethylene-10 tube
was catheterized and inserted into the subarachnoid space
under sevoflurane anesthesia and aseptic surgical condi-
tions, as described previously.
20 Following catheter implan-
tation, rats were individually housed. Those rats with post-
surgical neurological deficits were excluded from the study
and sacrificed immediately with an overdose of volatile
anesthetic. All testing was performed 5 days after intrathe-
cal catheterization.
The rats were divided into the six following groups:
group 1: 20% dimethylsulfoxide (DMSO, control); n = 7.
group 2: sildenafil 3, 10, and 30 µg, respectively; n = 7
each.
group 3: CGS 15943 0.03 µg (adenosine-receptor anta-
gonist); n = 6.
group 4: dihydroergocristine methanesulfonate 3 µg (sero-
tonin-receptor antagonist); n = 6.
group 5: sildenafil 30 µg with CGS 15943 0.03 µg; n = 6.
group 6: sildenafil 30 µg with dihydroergocristine metha-
nesulfonate 3 µg; n = 6.
Drugs
The following drugs were used in this study: sildenafil,
CGS 15943 (Sigma Aldrich, St. Louis, MO, USA), and
dihydroergocristine methanesulfonate (Sigma). The silde-
nafil was provided by Pfizer Korea. All drugs were dissolv-
ed in 20% DMSO. Intrathecal administration of these
agents was performed using a hand-driven, gear-operated
syringe pump. All drugs were delivered in a 10 µL vol-
ume, followed by an additional 10 µL of normal saline to
flush the catheter.
Nociceptive test
The formalin test was used as a nociceptive test.
5 The
formalin test was used as a nociceptive test.
5 The plantar
surface of the hind paw was injected with 50 µL of 5%
formalin solution subcutaneously using a 30-gauge needle.
Formalin injection produces characteristic pain behavior,
that is, a rapid, brief flexion of the injected paw, which was
defined as flinching. The total number of flinches was
recorded over 5 min intervals. Rats were observed for a
total period of 60 min. Formalin-induced flinches were
observed in a characteristic biphasic response. The initial
phase 1 (0-9 min) was followed by a relatively short quies-
cent period, which was then followed by a late phase 2
(10-60 min). Immediately following the completion of the
formalin test, the rats were sacrificed by a volatile anesthe-
tic overdose.
Experimental protocol
Four to five days after intrathecal catheterization, the rats
were placed in a restraining cylinder for the experiments.
After a 20-min habituation period, the rats were then
randomly assigned to one of the drug treatment groups.
Experiments were carried out in a blinded fashion. Intra-
thecal drugs were injected 10 min before formalin injec-
tion. The control consisted of intrathecal DMSO. The rats
were used only once for the formalin test.
Effects of intrathecal sildenafil
To investigate the antinociceptive effects of intrathecal
sildenafil (3, 10, 30 µg), the flinching response was exa-
mined during phases 1 and 2 in the formalin test for 60 min.
Effects of intrathecal CGS 15943 and 
dihydroergocristine on the sildenafil activity
Next, rats were pretreated with adenosine and serotonin
receptor antagonists to determine which receptor affected
sildenafil activity. These antagonists were administered
intrathecally 10 min before delivering the intrathecal sild-
enafil (30 µg), and the formalin was injected 10 min later.
The doses of the adenosine and serotonin receptor antago-
nists were based on pilot experiments and a previous
study,
21 as the maximum dosage that did not affect the con-
trol formalin response. The receptor antagonists used were
the adenosine receptor antagonist CGS 15943 (0.03 µg)
and the serotonin receptor antagonist dihydroergocristine
methanesulfonate (3 µg).
Animals were tested only once. The researcher who tested
the drugs was blinded to the drug given to each animal.
General behavior
In order to evaluate the behavioral changes of sildenafil,
CGS 15943, and dihydroergocristine methanesulfonate,
additional rats received the highest doses of agents used,
and were examined after intrathecal administration. Motor
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MATERIALS AND METHODSfunction was assessed using the placing-stepping reflex
and the righting reflex.
22
The former was evoked by drawing the dorsum of hind
paw across the edge of the table. Normally, rats try to put
their paws forward into a position for walking. The latter
was evaluated by placing the rat horizontally with its back
on the table; healthy rats produce immediate, coordinated
twisting of the body into an upright position. The pinna
and corneal reflexes were evoked by stimulating the ear
canal or cornea with string, respectively.
22 The healthy rats
spontaneously shook their heads or blinked. Normality of
behavior was judged as present or absent.
Statistical methods
Data are expressed as means ± SEM. The time-response
data are presented as the number of flinches. The dose-
response data are presented as the total sum of flinches in
each phase. The dose-response data for sildenafil were
analyzed using the Jonckheere test. Comparison of antago-
nism of the effect of sildenafil was carried out using the
unpaired t-test. p values < 0.05 were deemed to indicate
statistical significance.
Effects of intrathecal sildenafil
A subcutaneous injection of formalin into the hindpaw
resulted in a biphasic flinching response by the injected
paw. Fig. 1 shows the time course of intrathecal sildenafil,
administered 10 min before the formalin injection. In group
2, which received sildenafil, the flinching response during
phases 1 and 2 in the formalin test was significantly lower
than group 1 (Fig. 1). Intrathecal sildenafil produced dose-
dependent suppression of the flinching response during
phases 1 and 2 in the formalin test (Fig. 2).
Effects of intrathecal CGS 15943 and 
dihydroergocristine on sildenafil activity
In both groups 3 and 4, intrathecal CGS 15943 and dihyd-
roergocristine per se had little or no effect on the formalin-
induced flinching response, compared with group 1 (Fig. 3).
In both groups 5 and 6, the flinching response was signi-
ficantly higher, compared with group 2, indicating that
intrathecal CGS 15943 and dihydroergocristine reversed
the antinociceptive effect of sildenafil during phases 1 and
2 in the formalin test (Fig. 3).
Behavioral effects of sildenafil, CGS 15943, and 
dihydroergocristine
Pharmacological treatment with sildenafil, CGS 15943,
and dihydroergocristine produced normal behavior in ex-
perimental rats, as revealed by the righting and placing/
stepping reflexes.
DISCUSSION
In the formalin test, the characteristic biphasic pain beha-
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Fig. 1. Time-effect curve of sildenafil on flinching in the formalin test. Sildenafil
was administered intrathecally at time - 10 min and the formalin was injected
subcutaneously at time 0. Data are presented as the number of flinches. Each
line represents mean ±SEM.
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Fig. 2. Dose-response curve of intrathecal sildenafil on the flinching during
phases 1 (A) and 2 (B) in the formalin test. Data are presented as the sum of the
number of flinches in each phase. Intrathecal sildenafil produced dose-
dependent suppression of flinching in both phases. Each line represents mean
±SEM. Compared with the control [dimethylsulfoxid (DMSO)]. *p< 0.05.vior observed following formalin injection reflects a dis-
tinct phasic response which corresponds to essentially
different processes. The phase 1 response is believed to
represent a direct effect of formalin on sensory C fibers of
primary afferent, thus the phase 1 of the formalin test refl-
ects acute pain. On the other hand, the phase 2 response
appears to be prominent and represents an intensified pain
state in spite of a reduced level of afferent input, thus the
phase 2 of the formalin test reflects a facilitated state.
In this study, intrathecal administration of sildenafil, a
specific phosphodiesterase 5 inhibitor, dose-dependently
suppressed flinching during both phase 1 and phase 2 of
the formalin test, consistent with previous observations,
4,5,9
suggesting that sildenafil is active against acute pain and
facilitated state at the spinal level.
Phosphodiesterases occur widely in biological systems,
23
and are involved in the hydrolysis of cGMP. Eleven subfa-
milies of phosphodiesterase isoenzymes have been iden-
tified, based on their functional characteristics.
24 It has been
reported that phosphodiestrase 5, 6 and 9 are specific for
cGMP hydorolysis and, in particular, phosphodiesterase 5
seem to be the most relevant enzyme.
25 Guanylyl cyclase
catalyzes the formation of cGMP from guanosine triphos-
phate (GTP), leading to the synthesis of cGMP, whereas
cGMP-specific phosphodiesterase catalyzes the hydrolysis
of cGMP to GMP.
25 Thus, the intracellular cGMP concen-
tration is regulated by the action of guanylyl cyclase and
the rate of degradation by cGMP-specific phosphodies-
terase.
25,26
It has been proposed that cGMP may play a critical role
in the antinociceptive mechanism. Locally injected dibu-
tyryl-cGMP showed antinociception in inflammatory hy-
peralgesia model.
27 Intrathecally administered 8-bromo-
cGMP reduced the mechanical allodynia in a neuropathic
model.
28,29 Thus, our observations suggest that intrathecal
sildenafil produces an antinociceptive effect via the accu-
mulation of cGMP, through the inhibition of phosphodies-
terase 5.
Adenosine is an endogenous substance in the central
nervous system (CNS), where it is an important modulator
of neurotransmission and has been implicated in many
physiological functions, such as the regulation of arousal
and sleep, anxiety, cognition, and memory.
11,12 Adenosine
may play an important role in the modulation of nocicep-
tive inputs through adenosine A1 and adenosine A2 recep-
tors, which have been identified in the dorsal horn of the
spinal cord.
30 On the other hand, the adenosine A3 receptor
has not yet been identified. Recently, however, it was sug-
gested that the adenosine A3 receptor plays an important
role in the control of the facilitated state at the spinal level.
14
In addition to the above, the neurotransmitter serotonin
[5-hydroxytryptamine, (5-HT)] plays an important role in
the modulation of nociceptive transmission, and the major
site of action of 5-HT is the spinal cord.
13 Although multi-
ple 5-HT receptor subtypes have been defined in the CNS,
31
at least seven types of 5-HT receptor (including 5-HT1, 5-
HT2, 5-HT3, and 5-HT4) and several subtypes have so far
been identified in the spinal cord.
15,17
In this study, the antinociceptive effect of intrathecal
sildenafil was found to be reversed by intrathecal non-
specific adenosine and serotonin receptor antagonists.
These findings suggest that the increased cGMP with
sildenafil activates adenosine and serotonin receptors at the
spinal level. However, the antinociceptive effect of intra-
thecal sildenafil was not completely reversed by the intra-
thecal adenosine and serotonin receptor antagonists. These
results suggest that other mechanisms may also contribute
to the antinociceptive effect of sildenafil at the spinal level.
Previous work indicates that the NO-cGMP-PKG-potas-
sium channel pathway, GABAB receptor, and opioid recep-
tors are involved in sildenafil antinociception in the for-
malin model.
4-6,8-10
In summary, sildenafil, an inhibitor of phosphodiesterase
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Fig. 3. The antagonistic effects of intrathecal CGS 15943 (adenosine receptor
antagonist, 0.03 µg) and dihydroergocristine (HEC, serotonin receptor antagonist,
3 µg) on the antinociceptive effects of intrathecal sildenafil (30 µg) during phases
1 (A) and 2 (B) in the formalin test. The two antagonists and sildenafil were given
20 or 10 min respectively before injecting formalin. The data are presented as the
sum of the number of flinches in each phase. Each bar represents mean ±SEM.
Compared with sildenafil (30 µg): *p< 0.05, 
�p< 0.01.5, increased the cGMP level in the spinal cord, thereby
resulting in its antinociceptive effect in the formalin test.
Both adenosine and serotonin receptors may be involved
in the antinociceptive effects of sildenafil at the spinal
level. However, it is not known what effects the increased
cGMP, caused by sildenafil, exert on which subtypes of
adenosine and serotonin receptors. Further research includ-
ing a receptor-binding study will be necessary.
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